Adalvo announces successful DCP Submission for Dapagliflozin

We are pleased to announce our successful DCP submission for Dapagliflozin 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic partners.

Our product has been developed based on the reference brand Forxiga 10mg film-coated tablets, which is indicated in children, aged 10 years and above, for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and in adults for the treatment of symptomatic chronic heart failure and chronic kidney disease.

The brand sold approximately $8bn globally in 2022, having a significant growth potential with Global 3Y CAGR at +35%, according to IQVIA. 

Partner up now! 

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.

ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
camila.reinoso@adalvo.com - LATAM (exc. Brazil)

arni.baldursson@adalvo.com - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.